Histamine H2 receptors transfected in Chinese hamster ovary (CHO) cells are time-and dosedependently upregulated upon exposure to the H2 antagonists cimetidine and ranitidine. This effect appears to be H2 receptor-mediated as no change in receptor density was observed after H1 or H3 antagonist treatment or after incubation with the structural analogue of cimetidine, VUF 8299, which has no H2 antagonistic effects. By using transfected CHO cells expressing different densities of wild-type H2 receptors or an uncoupled H2Leut24Ala receptor, the histamine H2 receptor was found to display considerable agonist-independent H2 receptor activity. Cimetidine and ranitidine, which both induce H2 receptor upregulation, actually functioned as inverse agonists in those cell lines displaying spontaneous agonistindependent H2 receptor activity. Burimamide, on the other hand, was shown to act as a neutral antagonist and did as expected not induce H2 receptor upregulation after long-term exposure. The displayed inverse agonism of H2 antagonists appears to be a mechanistic basis for the observed H2 antagonist-induced H2 receptor upregulation in transfected CHO cells. These observations shed new light on the pharmacological classification of the H2 antagonists and may offer a plausible explanation for the observed development of tolerance after prolonged clinical use.
Following the discovery of burimamide as a selective histamine H2 receptor antagonist (1) various related drugs (cimetidine, ranitidine, famotidine, nizatidine) have proven to be of great importance in the regulation of gastric acid secretion (2) . The actual target of these drugs have recently been questioned (3, 4) , but is generally considered to be the H2 receptor on the gastric parietal cell (4) . As such, the H2 antagonists constitute currently one of the prominent therapies for duodenal and gastric ulcers (5) . These drugs have been widely prescribed and are currently also clinically evaluated as immunosuppressants (6) and for the treatment of central nervous system disorders (7) (8) (9) (10) .
The histamine H2 receptor is a member of the large multigene family of G-protein coupled receptors (GPCR) (11) . Functionality and expression of members of the GPCR family are generally dynamically regulated after agonist or antagonist exposure (12, 13) . Recently, histamine H2 receptors were shown to be rapidly desensitized (14-16), internalized (17) , and downregulated upon histamine or H2-agonist exposure (18) . Yet, despite their therapeutical importance, so far no detailed insights on the modulation of H2 receptor function by H2 antagonists have been published. In vivo modulation of H2 receptor function after treatment of H2 antagonists has been reported (2, (19) (20) (21) (22) . Prolonged H2 receptor blockade was found to result in increased parietal cell sensitivity to H2 agonists (22) , increased intragastric hyperacidity after abrupt withdrawal (21) , and the development of tolerance (2, 5, 19, 23, 24) . Coruzzi and Bertaccini (22) and Nwokolo et al. (21) hypothesized that these observations could be explained by an upregulation of H2 receptors. So far no data on the regulation of H2 receptor expression by H2 receptor antagonists have been presented, however.
Studies examining the molecular mechanism underlying H2 receptor function have been greatly facilitated by the cloning of the genes encoding the histamine H2 receptor (25) (26) (27) (28) . Model systems, expressing a homogeneous population of (mutant) H2 receptors, are currently available for studies regarding H2 receptor function and regulation (18, 29, 30) . In the present study we describe upregulation of H2 receptors after prolonged treatment of transfected Chinese hamster ovary (CHO) cells with some H2 antagonists. In our study, we observed that the histamine H2 receptor shows a spontaneous, histamine-independent activity. For some GPCRs, increased basal agonist-independent receptor activity can be inhibited by certain antagonists referred to as inverse agonists (for review, see refs. [31] [32] [33] [34] . Although this new pharmacological phenomenon is still a matter of debate (33-35), Milligan et al. (34) recently extended the concept of inverse agonism to GPCR regulation. While GPCR expression is reduced upon long-term agonist exposure, GPCR upregulation was hypothesized for inverse agonists (34) . We found that the H2 antagonists cimetidine and ranitidine act as inverse agonists at the H2 receptor. The displayed inverse agonism of these compounds indeed appears to be the mechanistic basis for the observed H2 antagonist-induced H2 receptor upregulation in transfected CHO cells (34 Cimetidine (100 ,uM, 24 hr) had no effect on the density of guinea-pig H1 receptors expressed in CHO cells (36) using the same expression vector (untreated cells, 100 ± 2% H1 receptors; cimetidine-treated cells, 91 ± 4% H1 receptors, mean ± SEM; n = 4). Moreover, pretreatment of CHOrH2WT cells for 24 hr with the phenyl analogue VUF 8299 (100 ,uM), devoid of H2 antagonistic activity at the guinea-pig right atrium (pA2 < 4) (39), did not affect the 125I-APT binding (VUF 8299-treated cells, -3 + 11% upregulation). Furthermore, the histamine H1 and H3 antagonists, triprolidine (1 ,uM) (-3 ± 10% upregulation, mean ± SEM; n = 3) and thioperamide (1 ,uM) (12 ± 11% upregulation, mean ± SEM; n = 3) did not affect the amount of H2 receptors of CHOrH2WT cells after 24-hr incubation.
Spontaneous Agonist-Independent H2 Receptor Activity. As recently hypothesized by Milligan et al. (34) , the antagonistinduced GPCR upregulation might be ascribed to an inhibition of spontaneous GPCR activity. We therefore determined basal and forskolin-induced cAMP levels in CHO cells expressing different levels of rat histamine H2 receptors. The basal level of cAMP and the forskolin (10 ,M)-induced formation of cAMP increased upon elevation of H2 receptor expression levels (Table 1 ). Already at a H2 receptor density of 286 fmol/mg protein (CHOrH2WT9), basal cAMP levels as well as forskolin-induced cAMP levels were found to be significantly increased compared with untransfected CHO cells. This effect was even more pronounced at higher expression levels (Table 1 ). In contrast, basal levels and forskolin-induced formation of cAMP in CHO cells expressing high levels of the mutant H2Leu124Ala receptor, which was previously found to be uncoupled from its Gs protein (18), were not significantly elevated (Table 1) .
Inverse Agonism of H2 Antagonists. In view of the observed spontaneous agonist-independent H2 receptor activity, we investigated whether cimetidine exhibited negative intrinsic activity by reducing the basal levels of cAMP. Incubation of CHOrH2WT cells with increasing concentrations of cimetidine resulted in a dose-dependent decrease of basal levels of cAMP with an IC50 value of 1.2 ± 0.2 ,uM (mean + SEM; n = 4) (Fig. 2A) . The phenyl analogue of cimetidine, VUF 8299, on the other hand, did not exhibit negative intrinsic activity Pharmacology: Smit et al. ( Fig. 2A) . Basal levels of cAMP (62 ± 5 pmol cAMP/mg protein, mean + SEM; n = 5) in CHOrH2WT9 cells were also found to be significantly reduced by 100 ,uM cimetidine (48 + 5 pmol/mg protein, 23% reduction, mean + SEM; n = 3), while no effect was observed when CHOrH2WT6 cells were exposed to 100 ,uM cimetidine (control, 42 + 7 pmol cAMP/mg protein; cimetidine-treated cells, 46 + 9 pmol cAMP/mg protein, mean ± SEM; n = 4). In CHOrH2Leu124Ala cells in which basal cAMP levels were comparable to untransfected CHO cells (Table 1) , cimetidine did not exhibit any negative intrinsic activity either (Fig.  2B) . Moreover, no effect on basal cAMP levels was observed when untransfected CHO cells were exposed to 100 ,uM cimetidine (control, 37 + 4 pmol cAMP/mg protein; cimetidine-treated cells, 39 + 2 pmol cAMP/mg protein, mean + SEM; n = 5).
Besides cimetidine, another H2 antagonist ranitidine was shown to display negative intrinsic activity as well (Fig. 3A) . As can be seen in Fig. 3A , a dose-dependent decrease of basal cAMP levels was observed when CHOrH2WT cells were incubated with increasing concentrations of ranitidine. Ranitidine displayed a higher negative intrinsic activity than cimetidine (Fig. 3A) . As found for cimetidine, the IC50 value of ranitidine for the inhibition of basal levels of cAMP correlated with its H2 receptor affinity (Table 2) . Remarkably, burimamide, the first identified H2 antagonist showing reasonable affinity for the H2 receptor (Ki value, 5.5 ,uM), did not affect the basal levels of cAMP in CHOrH2WT cells (Fig. 3A) . Although burimamide did not display negative intrinsic activity, 100 ,uM burimamide was able to inhibit the histamine (30 nM)-induced cAMP production in CHOrH2WT cells significantly (Fig. 3B ) and may thus be classified as a neutral antagonist. According to the characteristics of a neutral antagonist, 100 ,iM burimamide inhibited the agonist response as well as the cimetidine (1 ,uM)-induced reduction of basal levels of cAMP significantly (Fig. 3B ).
Inverse Agonism of H2 Antagonists and H2 Receptor Upregulation. Long-term (24-hr) incubation of CHOrH2WT9 cells, displaying increased basal activity, with 100 ,uM of the inverse agonist cimetidine also led to a significant increase in 125I-APT binding sites (83 ± 9% upregulation, mean ± SEM; n = 3) (Table 1 ). Yet, in cells that did not show increased basal receptor activity, CHOrH2WT6 and CHOrH2Leu124Ala cells, no significant increase in 125I-APT binding sites was observed after long-term incubation with 100 ,uM cimetidine (Table 1) . Moreover, long-term incubation (24 hr) of CHOrH2WT cells with 10 ,uM of the inverse agonist ranitidine was shown to induce a significant increase in 1251-APT binding sites, whereas 1 mM of the neutral antagonist burimamide did not induce a significant change in H2 receptor density (Table 2) The cimetidine-induced H2 receptor upregulation appears to be H2 receptor-mediated as VUF 8299, a cimetidineanalogue devoid of H2 receptor activity (39) or H1 or H3 antagonists do not affect H2 receptor expression. According to classical models for drug-GPCR interaction, GPCR antagonists are believed to prevent the binding of agonists to the receptor (40) . Consequently, their physiological effect, including receptor upregulation, is ascribed to their ability to prevent activation/downregulation of receptors by endogenous hormones or neurotransmitters. However, there is now substantial evidence that contradicts this concept. For some GPCRs, certain antagonists were shown to induce effects opposite to those observed by agonists, thereby displaying negative intrinsic activity, also referred to as inverse agonism (see refs. [31] [32] [33] [34] . Evidence of inverse agonism by GPCR antagonists came from experiments with constitutively active GPCR mutants (41) (42) (43) (44) , certain overexpressed WT GPCRs (45) (46) (47) (48) (49) (50) (51) , and transgenic mice with myocardial overexpression of the f32-adrenergic receptor (52) . In the various models, the respective GPCRs exhibit a spontaneous, agonist-independent receptor activity. This basal receptor activity was shown to be inhibited by some antagonists (inverse agonists), but not by all antagonists (neutral antagonists). Currently, an (41) (42) (43) (44) . Yet, inverse agonism has recently also been observed in myometrial cells (53) , erythrocytes (54) , and cardiomyocytes (55, 56) , suggesting that inverse agonism might be of physiological relevance.
In the present study we have shown that the histamine H2 receptor displays agonist-independent basal activity, which increases upon elevation of receptor density. Already,_ at a H2 receptor density of 286 fmol/mg protein (CHOrH2WT9 cells), a significant increase of basal and forskolin-induced cAMP formation is observed. Evidence of spontaneous, agonist-independent activity of H2 receptors was supported by experiments using the H2Leu124Ala receptor mutant. Previously, we observed that this mutation resulted in a loss of agonist high-affinity binding sites and concommittant loss of histamine potency to induce the production of cAMP (18) . CHO (34) our findings show that inverse agonists cause GPCR upregulation, when spontaneous, agonist-independent receptor activity is displayed.
As already stated, although very effective in humans for treating peptic ulcers, long-term H2 antagonist treatment is complicated in some patients by the development of tolerance and recurrency (2, 5, 19, 23, 24, 57) . It is tempting to speculate that the inverse agonism displayed by the tested H2 antagonists, consequently resulting in an upregulation of H2 receptors, contributes to the development of tolerance after chronic treatment (2, 5, 19, 23, 24) . In view of this hypothesis, the use of a neutral H2 antagonist might offer advantages, as inverse agonists are more likely to cause H2 receptor upregulation and thus development of tolerance. Unfortunately, the neutral antagonist burimamide is clinically not applicable (58) and is therefore at present not available for investigation in humans.
Taken together, our study shows that already at moderate receptor densities histamine H2 receptors are spontaneously active and the H2 antagonists cimetidine and ranitidine, previously thought to act as competitive antagonists, actually function as inverse agonists. The inverse agonism displayed appears to be a mechanistic basis for the observed H2 antagonist-induced H2 receptor upregulation in CHO cells. It is clear that these findings should alter the view regarding the action of H2 antagonists and may have implications for effective drug therapy. Moreover, our study shows that an inverse agonist and a neutral antagonist differentially regulate H2 receptor expression. These observations may be of general importance for the understanding of GPCR regulation.
